BioSpace News Archive

Cook Medical, a global medical device manufacturer, has partnered with Bedal International, a company specializing in catheter securement devices marketed under the brand FlexGRIP®.

IceCure Medical Ltd. announced ProSense® was featured in a number of sessions, including one titled “Minimal access imaging guided therapies: cryoablative therapies in breast pathologies,” at the fourth Breast Imaging & Interventional Techniques conference at Tata Memorial Centre in Mumbai, India on February 24, 2024.

Bicara Therapeutics today announced that company leadership will participate in two upcoming investor conferences in March.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.

Aria CV, Inc today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.

Cerevance today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Capricor Therapeutics announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March.

Cryoport, Inc. today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.

Sengenics Corporation LLC , a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has entered into a sales distribution and services agreement with Chinese distributor Shanghai Universal Biotech Co., Ltd. (“UniV”).

Cannabis genetics company Phylos®, along with People Science, a direct-to-consumer scientific research and technology company, has conducted an IRB-approved, double-blind clinical research study on the effects of rare cannabinoid tetrahydrocannabivarin (THCV).